- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07701421
Use of a Virtual Reality Headset During Prostate Biopsy Under Local Anesthesia to Improve the Patient's Experience
Use of a Virtual Reality Visor (REALICA®) as an Supplementary Tool to Local Anesthesia in Patients Undergoing Prostate Biopsy: A Randomized Clinical Trial
This is a post-market clinical investigation evaluating the effect of immersive virtual reality (VR) as an adjunct to standard local anesthesia during transperineal prostate biopsy.
Transperineal prostate biopsy under local anesthesia is commonly associated with patient anxiety, procedural discomfort, and vasovagal reactions, which may negatively impact patient experience and procedural tolerability. Non-pharmacological distraction techniques such as immersive VR have shown potential to reduce perceived pain and anxiety during short, invasive medical procedures by modulating cognitive attention and emotional response.
This study investigates whether the use of an immersive VR headset, added to standard local anesthesia, can reduce peri-procedural anxiety and pain compared to standard care alone. The intervention is designed to provide continuous audiovisual immersive distraction starting shortly before the procedure and continuing throughout the biopsy, without altering standard clinical workflow or increasing procedural invasiveness.
This is a randomized, controlled, parallel-group, 1:1 superiority trial with a single-blind (assessor-blinded) design. Participants undergoing transperineal prostate biopsy under local anesthesia will be randomly assigned to one of two groups: standard local anesthesia alone (control arm) or standard local anesthesia plus immersive VR (experimental arm).
The primary objective is to evaluate whether immersive VR reduces peri-procedural anxiety and pain compared with standard local anesthesia alone. Secondary objectives may include evaluation of patient satisfaction, tolerability of the VR intervention, and incidence of vasovagal reactions or procedural interruptions.
The study aims to generate evidence on the feasibility and clinical benefit of integrating immersive VR as a non-pharmacological supportive tool in urological diagnostic procedures.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Italy
-
Milan, Italy, Italien, 20132
- IRCCS Ospedale San Raffaele
-
Kontakt:
- Simone Scuderi
- Telefonnummer: +39 02 2643 6922
- E-mail: scuderi.simone@hsr.it
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- The participant provides written informed consent for the trial
- Male participants who are at least 18 years of age on the day of signing informed consent
- Men undergoing transperineal prostate biopsy under local anesthesia
Exclusion Criteria:
- Visual or hearing impairment that would prevent effective use of the virtual reality device
- History of epilepsy or seizure disorders
- Severe motion sickness or known susceptibility to cybersickness
- Severe psychiatric disorders that, in the investigator's judgment, could interfere with study participation or outcome assessment
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm A (Control)- Transperineal Prostate Biopsy under Local Anesthesia
Participants undergo transperineal prostate biopsy performed under standard clinical practice using local anesthesia.
Local anesthetic is administered according to institutional protocol prior to the procedure.
No additional interventions or supportive devices are used in this arm.
Patients receive routine peri-procedural monitoring and care as per standard of care.
|
Transperineal prostate biopsy performed under standard clinical practice using local anesthesia administered according to institutional protocol.
No additional supportive or experimental interventions are applied.
|
|
Eksperimentel: Arm B (Experimental)- Local anesthesia + immersive VR headset
Participants undergo transperineal prostate biopsy performed under standard clinical practice using local anesthesia, with the addition of an immersive virtual reality (VR) headset as a supportive intervention.
The VR device is applied approximately 3-5 minutes before the start of the procedure and is worn continuously throughout the biopsy.
The VR experience is used as a non-pharmacological distraction tool intended to reduce peri-procedural anxiety and pain.
|
Transperineal prostate biopsy performed under standard local anesthesia with the addition of an immersive virtual reality (VR) headset used as a non-pharmacological distraction tool.
The VR device is applied approximately 3-5 minutes before the start of the procedure and worn continuously throughout the biopsy.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procedural Pain Intensity
Tidsramme: Immediately after completion of the biopsy procedure
|
Pain will be assessed using the Visual Analogue Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain)
|
Immediately after completion of the biopsy procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Procedural anxiety
Tidsramme: Immediately post-procedure
|
Assessed using the State-Trait Anxiety Inventory Form Y-1 (STAI-Y1).
The STAI-Y1 total score ranges from 20 to 80, with higher scores indicating greater anxiety
|
Immediately post-procedure
|
|
Decision regret
Tidsramme: 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the validated Decision Regret Scale (DRS).
The Decision Regret Scale is a 5-item questionnaire assessing regret following a healthcare decision.
Scores range from 0 to 100, with higher scores indicating greater decision regret.
|
1 month (Day 30 ± 5 days) after the procedure
|
|
Urinary incontinence
Tidsramme: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF).
Total scores range from 0 to 21, with higher scores indicating greater severity of urinary incontinence.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Lower urinary tract symptoms
Tidsramme: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the International Prostate Symptom Score (IPSS).
Total scores range from 0 to 35, with higher scores indicating greater severity of lower urinary tract symptoms.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Sexual function
Tidsramme: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the International Index of Erectile Function (IIEF).
The IIEF is a validated 15-item questionnaire assessing male sexual function.
Total scores range from 5 to 75, with higher scores indicating better sexual function.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Health-related quality of life
Tidsramme: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ).
The EORTC QLQ is a validated questionnaire assessing health-related quality of life.
Scores are transformed into a 0 to 100 scale.
For functional scales and global health status, higher scores indicate better quality of life, whereas for symptom scales, higher scores indicate greater symptom burden.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Depressive symptoms
Tidsramme: Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
Assessed using the Patient Health Questionnaire-9 (PHQ-9).
The PHQ-9 is a 9-item questionnaire assessing depressive symptoms.
Total scores range from 0 to 27, with higher scores indicating greater severity of depressive symptoms.
|
Baseline and 1 month (Day 30 ± 5 days) after the procedure
|
|
Post-procedural complications
Tidsramme: During the procedure and up to 30 days after the procedure
|
Collection of all reported complications related to the biopsy procedure, including vasovagal reactions and other adverse events.
|
During the procedure and up to 30 days after the procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Andre undersøgelses-id-numre
- VR-biopsy
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .